Objective To explore the effect of S100A1 on the proliferation of human thyroid cancer SW579 cells and its mechanism. Methods The human thyroid cancer data sets GSE50901 and GSE138198 were selected, and R software was used to screen the differentially expressed genes in thyroid cancer tissues and normal thyroid tissues. The differentially expressed genes were verified with TGCA database. CCK-8 experiment was used to detect the effect of S100A1 knockdown or overexpression on the proliferation of human thyroid cancer SW579 cell. Western Blot was used to detect the effect of S100A1 on the WNT/β-catenin signaling pathway. Results A joint analysis of the data sets GSE50901 and GSE138198 showed that 97 genes were up-regulated in both data sets, and 46 genes were down-regulated. S100A1 gene is highly expressed in thyroid cancer. Knockdown of S100A1 could inhibit the proliferation of SW579 cells, and overexpression of S100A1 could promote the proliferation of SW579 cells. GSEA analysis found that WNT signal pathway was significantly enriched after knocking down S100A1 in SW579 cells, and the signal pathway activity was reduced. Western Blot results showed that the protein expression levels of β-catenin, c-myc and cyclin D1 in the siS100A1 group were significantly lower than those in the siNeg group, while the protein expression levels of β-catenin, c-myc and cyclin D1 in the S100A1 group were significant higher than those in the EGFP group. Conclusion S100A1 is highly expressed in thyroid cancer. Knockdown of S100A1 might inhibit the proliferation of thyroid cancer SW579 cells by inhibiting the activity of WNT/β-catenin signaling pathway.

Objective To compare the difference of three blood coagulation function assays in patients with blood component transfusion. Methods Sixty patients who had received platelets and/or plasma transfusions were selected to carry ouy routine haemostatic assays,thrombelastogram（TEG）,and Sonoclot analysis. The correlation and consistency of the three Methods were evaluated. Results A significant correlation of the R,ACT,PT,APTT and INR were observed in the three Methods. The ANGLE,CR and FIB,that reflect fibrinogen founctions,were also highly correlated,and similar correlation was noted in the MA,TP and PLT that indicate platelet founctions. Consistency of the parameters of R,ACT,and ANGLE and CR exists but the poor uniformity of the other parameters was seen. A significant correlation of TP and INR was observed with bleeding of patients. Conclusions A satisfactory correlation in routine coagulation tests,TEG and Sonoclot exists. Evaluation of coagulation founction should be based on the laboratory profile tests together with clinical menifestations of the patients.

Objective Marvelous advancements have been made in cancer therapies to improve clinical outcomes over last few years. However, therapeutic resistance has always been a major difficulty in cancer therapy, with extremely complicated mechanisms remain elusive. N6-methyladenosine (m6A) RNA modification, a hotspot in epigenetics, has gained growing attention as a potential determinant of therapeutic resistance. As the most prevalent RNA modification, m6A is involved in every links of RNA metabolism, including RNA splicing, nuclear export, translation and stability. Three kinds of regulators, methyltransferase (writer), demethylase (eraser) and RNA binding proteins (reader), together orchestrate the dynamic and reversible process of m6A modification. Herein, we primarily reviewed the regulatory mechanisms of m6A in therapeutic resistance, including chemotherapy and targeted therapy. Then we discussed the clinical potential of m6A modification to overcome resistance and optimize cancer therapy. Additionally, we proposed prospects of m6A modification for future research.

Objective To compare the consistence of HPV typing tests by using three kits that are domestically available. Methods A total of 82 positive samples and 10 negative samples were collected that had been detected with Liferiver kits in recent 2 months and the Results of HPV typing tests were compared for the agreements with the kits purchased from other two companies of Kaipu and Amply. Results The repeatability of the Results in the three domestic kits were 95.6 %,96.7% and 95.6%,respectively. The consistent rate was 51.0%（47/92）,the partial consistent rate was 23.9%（22/92）,and the inconsistent rate was 25.0%（23/92）.The consistent rate of 86.4%（32/37）was seen in detections of single type infection,22.2%（10/45）in multiple infections,and the partial consistent rate found to be 48.9%（22/45）. Conclusion of the Results in the three domestic kits varied,and the hospital should be fixed for HPV typing before and after treatments of the infection.

Objective To investigate the level and clinical value of autoantibodies in patients with malignant pulmonary nodules. Methods Seventy-one patients with asymptomatic pulmonary nodules admitted to our hospital from November 2018 to January 2019 were enrolled, including 58 malignant pulmonary nodules and 13 benign pulmonary nodules. And ten healthy people as control group.The levels of p53, PGP9.5, SOX2, GAGE7, GBU4-5, MAGEA1 and CAGE in all specimens were detected by ELISA kit. The ROC curve was used to analyze the diagnostic value of autoantibodies for malignant pulmonary nodules. Results Compared with the benign pulmonary nodules group and the normal control group, the level of autoantibodies in the malignant nodules of the lungs was significantly increased (P<0.05);ROC curve analysis showed that seven autoantibodies were important for the differential diagnosis of benign and malignant pulmonary nodules (AUC>0.5, P<0.05), and seven autoantibodies combined detection could improve the differential diagnosis efficiency (AUC=0.822);The positive detection rate of lung malignant nodules was 81.7% by LDCT and was increased to 94.0% combining with autoantibodies detection (P<0.05). Conclusion Serum autoantibody detection has potentialclinical value in the differential diagnosis of benign and malignant pulmonary nodules.